Novel pharmacological therapies for the treatment of AIDS-related Kaposi's sarcoma

被引：5
作者：
Cattelan, AM [1 ]
Trevenzoli, M [1 ]
Aversa, SML [1 ]
机构：
[1] Univ Padua, Dept Infect Dis, I-35128 Padua, Italy
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2004年 / 13卷 / 05期
关键词：
AIDS; antiangiogenic agents; antiretroviral therapy; antitumour treatment; human herpes virus-8; Kaposi's sarcoma;
D O I：
10.1517/13543784.13.5.501
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Kaposi's sarcoma (KS) is the most common cancer associated with AIDS. KS aetiology and pathogenesis are still poorly defined and no definitive treatment has yet been identified. However, the introduction in 1996 of highly active antiretroviral therapy as a standard of care for those infected with HIV-1 determined a strong protection against the development of opportunistic infections, as well as a remission of pre-existing complications, including KS. Under highly active antiretroviral therapy, KS in particular has shown the highest clinical response rate reported to date among AIDS patients. Furthermore, recent insights into the pathogenetic mechanisms involved in KS development have provided new hope for a response and improved survival in patients with AIDS-related KS. This paper presents an overview of the current knowledge concerning pharmacological approaches to treating this disease. Newer treatments such as PEGylated liposomal anthracyclin, paclitaxel and pathogenesis-based strategies are also discussed.
引用
收藏
页码：501 / 513
页数：13
相关论文
共 124 条
[1]   9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma -: Results of a phase 2 multicenter clinical trial [J].
Aboulafia, DM ;
Norris, D ;
Henry, D ;
Grossman, RJ ;
Thommes, J ;
Bundow, D ;
Yocum, RC ;
Stevens, V .
ARCHIVES OF DERMATOLOGY, 2003, 139 (02) :178-186
[2]   Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 [J].
Aoki, Y ;
Jaffe, ES ;
Chang, Y ;
Jones, K ;
Teruya-Feldstein, J ;
Moore, PS ;
Tosato, G .
BLOOD, 1999, 93 (12) :4034-4043
[3]  
Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823
[4]  
Barillari G, 1999, BLOOD, V94, P663
[5]  
Belotti D, 1996, CLIN CANCER RES, V2, P1843
[6]   KAPOSIS SARCOMA AMONG PERSONS WITH AIDS - A SEXUALLY-TRANSMITTED INFECTION [J].
BERAL, V ;
PETERMAN, TA ;
BERKELMAN, RL ;
JAFFE, HW .
LANCET, 1990, 335 (8682) :123-128
[7]   The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin [J].
Berry, G ;
Billingham, M ;
Alderman, E ;
Richardson, P ;
Torti, F ;
Lum, B ;
Patek, A ;
Martin, FJ .
ANNALS OF ONCOLOGY, 1998, 9 (07) :711-716
[8]   The epidemiology of AIDS-related neoplasms [J].
Biggar, RJ ;
Rabkin, CS .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1996, 10 (05) :997-&
[9]   Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma [J].
Bodsworth N.J. ;
Block M. ;
Bower M. ;
Donnell D. ;
Yocum R. .
American Journal of Clinical Dermatology, 2001, 2 (2) :77-87
[10]   INTRALESIONAL VINBLASTINE FOR CUTANEOUS KAPOSI-SARCOMA ASSOCIATED WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME - A CLINICAL-TRIAL TO EVALUATE EFFICACY AND DISCOMFORT ASSOCIATED WITH INJECTION [J].
BOUDREAUX, AA ;
SMITH, LL ;
COSBY, CD ;
BASON, MM ;
TAPPERO, JW ;
BERGER, TG .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1993, 28 (01) :61-65
12345678910